EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention

Luis Ortega-Paz, Wilbert Bor, Francesco Franchi, Wout W A van den Broek, Fabiana Rollini, Salvatore Giordano, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Haroutioun Garabedian, Tala Al Saleh und 13 weitere

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2024.03.027 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Luis Ortega-Paz und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA. Electronic address: https://twitter.com/O…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Ticagrelor, Clopidogrel, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known as dual antithrombotic therapy [DAT]) is the treatment of choice. However, there are concerns for individuals with impaired response to clopidogrel. OBJECTIVES: The authors sought to assess the pharmacodynamic (PD) effects of clopidogrel vs low-dose ticagrelor in patients with impaired clopidogrel response assessed by the ABCD-GENE score. METHODS: This was a prospective, randomized PD study of NOAC-treated patients undergoing PCI. Patients with an ABCD-GENE score ≥10 (n = 39), defined as having impaired clopidogrel response, were randomized to low-dose ticagrelor (n = 20; 60 mg twice a day) or clopidogrel (n = 19; 75 mg once a day). Patients with an ABCD-GENE score

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionTicagrelorClopidogrelPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsAnticoagulantsReceptors, Purinergic P2Y12HumansMaleProspective StudiesFemaleAgedMiddle AgedAdministration, OralTreatment OutcomeTime FactorsPlatelet Function TestsPlatelet AggregationPhosphoproteinsBlood PlateletsMicrofilament ProteinsCoronary Artery DiseaseCell Adhesion MoleculesDrug ResistanceDual Anti-Platelet TherapyVasodilator-Stimulated Phosphoprotein

Stichwörter der Autor:innen

anticoagulantsclopidogrelcoronary artery diseasepercutaneous coronary interventionpharmacodynamicplateletsticagrelor

Substanzen

TicagrelorClopidogrelPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsP2RY12 protein, humanAnticoagulantsReceptors, Purinergic P2Y12Vasodilator-Stimulated PhosphoproteinPhosphoproteinsMicrofilament Proteins

Autor:innen und Institutionen

  • Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA. Electronic address: https://twitter.com/Ortega_Paz.
  • St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA.
  • Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.
  • Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA. Electronic address: dominick.angiolillo@jax.ufl.edu.

Zitieren

APA

Ortega-Paz, L., Bor, W., Franchi, F., van den Broek, W. W. A., Rollini, F., Giordano, S., Galli, M., Been, L., Ghanem, G., Shalhoub, A., Garabedian, H., Al Saleh, T., Uzunoglu, E., Zhou, X., Rivas, A., Pineda, A. M., Suryadevara, S., Soffer, D., Mahowald, M. K., …, & Angiolillo, D. J. (2024). P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.03.027

Vancouver

Ortega-Paz L, Bor W, Franchi F, van den Broek WWA, Rollini F, Giordano S, et al. P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.03.027

BibTeX
@article{OrtegaPaz2024,
  author = {Ortega-Paz, Luis and Bor, Wilbert and Franchi, Francesco and van den Broek, Wout W A and Rollini, Fabiana and Giordano, Salvatore and Galli, Mattia and Been, Latonya and Ghanem, Ghussan and Shalhoub, Awss and Garabedian, Haroutioun and Al Saleh, Tala and Uzunoglu, Ekin and Zhou, Xuan and Rivas, Andrea and Pineda, Andres M and Suryadevara, Siva and Soffer, Daniel and Mahowald, Madeline K and Choi, Calvin Y and Zenni, Martin M and Phoenix, Fladia and Ajjan, Ramzi A and Ten Berg, Jurrien M and Angiolillo, Dominick J},
  title = {P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2024.03.027}
}
Kostenlos starten →